TipHub

₹222.57

▼ -1.01 -0.45%

30 Jul 2026

NSE Listed · Pharmaceuticals

ST-ASM · ASM 1
What does ST-ASM · ASM 1 mean?
BSE · Short Term Additional Surveillance Measure (ASM 1)ST-ASM catches short bursts: a beta-adjusted close-to-close move beyond ±25% in 5 trading days (or ±40% in 15) combined with concentrated trading — or a 75%+ monthly range with fewer than 100–200 unique traders. Practical meaning: margins jump to 50–100% for a few weeks to cool a spike; it either lapses quickly or escalates into LT-ASM if the move sustains.Criteria: Short-term (5 / 15 / 30-day) price-volume abnormality — high-low and close-to-close price variation over the window. Adds 100% margin and a 5% (then 2%) price band.Exchange notice · 2026-07-13
NSE · Short Term Additional Surveillance Measure (ASM 1)ST-ASM catches short bursts: a beta-adjusted close-to-close move beyond ±25% in 5 trading days (or ±40% in 15) combined with concentrated trading — or a 75%+ monthly range with fewer than 100–200 unique traders. Practical meaning: margins jump to 50–100% for a few weeks to cool a spike; it either lapses quickly or escalates into LT-ASM if the move sustains.Criteria: Short-term (5 / 15 / 30-day) price-volume abnormality — high-low and close-to-close price variation over the window. Adds 100% margin and a 5% (then 2%) price band.Exchange notice · 2026-07-14

Ind-Swift Laboratories Ltd. (INDSWFTLAB)

Volume: 80,596Avg Vol 1W: 4,28,753Avg Vol 1M: 9,14,53652W Range:₹87.15₹248.45
NSE BSE www.indswiftlabs.com AI Report
Key Ratios
Checked just now
Market Cap₹1,936 Cr
Current Price₹222.57
Previous Close₹223.58
High / Low (52w)₹248.45 / ₹87.15
Volume80,596
Avg Vol (1W)4,28,753
Avg Vol (1M)9,14,536
Stock P/E122.97
Book Value₹159.38
Dividend Yield0%
ROE3.57%
ROA2.47%
Revenue (TTM)—
Revenue Growth-67.13%
Profit Margin6.61%
Total Debt₹8 Cr
Shares Outstanding9 Cr
Face Value₹10
EPS (TTM)₹1.81
P/B1.4
Debt / Equity0.01
50 DMA₹191.86
200 DMA₹136.52
Day change-0.45%
SurveillanceST-ASM · ASM 1
Price Chart
₹222.57▲ 111.63% · 1Y
₹246₹881.3Cr
2025-07-30
2026-07-30

20-day avg volume: 9.4L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 13% YoY.
  • Net profit is growing year over year.
Cons
  • Stock trades at a high P/E of 123.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹33 Cr₹12 Cr₹129 Cr₹138 Cr₹153 Cr₹153 Cr₹151 Cr₹170 Cr
EBITDA₹1 Cr₹1 Cr₹4 Cr₹-12 Cr₹12 Cr₹12 Cr₹23 Cr₹15 Cr
Net Profit₹1 Cr₹0 Cr₹-5 Cr₹222 Cr₹9 Cr₹8 Cr₹10 Cr₹15 Cr
EPS————————
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹3 Cr₹122 Cr₹643 Cr₹150 Cr₹148 Cr₹150 Cr₹153 Cr₹173 Cr
EBITDA₹1 Cr₹10 Cr₹38 Cr₹-16 Cr₹11 Cr₹13 Cr₹24 Cr₹14 Cr
Net Profit₹0 Cr₹-1 Cr₹250 Cr₹218 Cr₹8 Cr₹9 Cr₹11 Cr₹15 Cr
EPS——35.21—————
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹2,023 Cr₹1,924 Cr₹1,870 Cr₹1,818 Cr₹1,801 Cr₹1,824 Cr₹1,165 Cr₹1,438 Cr
Total Liabilities₹1,470 Cr₹1,336 Cr₹1,229 Cr₹1,215 Cr₹1,200 Cr₹1,142 Cr₹234 Cr₹265 Cr
Equity₹553 Cr₹588 Cr₹641 Cr₹603 Cr₹601 Cr₹682 Cr₹931 Cr₹1,173 Cr
Total Debt————————
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹73 Cr₹-64 Cr₹125 Cr₹134 Cr₹150 Cr₹195 Cr₹-163 Cr₹-25 Cr
Investing₹-17 Cr₹-12 Cr₹-9 Cr₹-10 Cr₹5 Cr₹-13 Cr₹-104 Cr₹-110 Cr
Financing₹-62 Cr₹100 Cr₹-133 Cr₹-124 Cr₹-141 Cr₹-186 Cr₹699 Cr₹69 Cr
Free Cash Flow₹73 Cr₹-64 Cr₹125 Cr₹134 Cr₹150 Cr₹195 Cr₹-163 Cr₹-25 Cr
Shareholding
Promoter 42.93% Institutions 10.87% Public 46.2%
Efficiency & Working Capital
ROCE1.1%
Interest Coverage3
Dividend Payout—
Debtor Days107 d
Inventory Days74 d
Payable Days72 d
Cash Conversion Cycle109 d
Working Capital Days181 d
Shareholding Details

As of 2026-06-30

Promoter42.9%
FII10.7%
DII0.2%
Institutions10.9%
Public46.2%
Promoter Pledge0%
No. of Shareholders40,881
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2024Mar 2025Jun 2025Jul 2025Jul 2025Aug 2025Aug 2025Sept 2025Dec 2025Feb 2026Mar 2026Jun 2026
Promoters42%40.9%40.9%36.8%36.8%39.5%39.5%39.5%39.5%43.1%43%42.9%
FIIs0.5%3.1%4.3%17%17%14.9%14.9%14.8%14.3%13.8%13.9%10.7%
DIIs0.9%0.9%0.9%0.8%0%0.7%0%0.7%0.7%0.2%0%0.2%
Public56.6%55.1%53.9%45.5%46.2%44.9%45.6%45%45.5%43%43.1%46.2%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders28,75228,11728,70928,90728,90743,98443,98443,78042,12140,40439,22240,881
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Essix Biosciences LimitedShareholding of Promoter and Promoter Group37.8%3.29 Cr
Zeal Global Opportunities FundPublic Shareholding4.6%40,13,561
Nova Global Opportunities Fund Pcc - TouchstonePublic Shareholding3%25,72,991
Panchkula Finvest Private LimitedPublic Shareholding2.4%20,91,619
Ashokkumar ChandakPublic Shareholding2.2%19,23,991
Zaki Abbas NasserPublic Shareholding2.1%18,35,000
Pranav JonejaPublic Shareholding1.4%12,51,400
Rameshkumar Javerchand JainPublic Shareholding1.4%12,00,000
Sharwan Singh GuleriaPublic Shareholding1.2%10,79,978
Navrattan MunjalShareholding of Promoter and Promoter Group1.2%10,12,479
Ark Global Emerging Companies, LpPublic Shareholding1.1%9,85,200
Rishav MehtaShareholding of Promoter and Promoter Group1.1%9,52,357
Nisarg Ajaykumar VakhariaPublic Shareholding1%9,05,000
S. R. MehtaShareholding of Promoter and Promoter Group0.6%5,38,980
Himanshu JainShareholding of Promoter and Promoter Group0.6%4,81,256
Gopal MunjalShareholding of Promoter and Promoter Group0.4%3,54,479
V.r. MehtaShareholding of Promoter and Promoter Group0.4%3,41,104
Sunita JainShareholding of Promoter and Promoter Group0.4%3,17,960
Ravi MehtaShareholding of Promoter and Promoter Group0.1%1,07,170
Neeta MunjalShareholding of Promoter and Promoter Group0.1%98,790
Nidhi MunjalShareholding of Promoter and Promoter Group0.1%87,445
Meenakshi MehtaShareholding of Promoter and Promoter Group0.1%71,746
Annie MehtaShareholding of Promoter and Promoter Group0%26,574
Sahil MunjalShareholding of Promoter and Promoter Group0%25,957
Ishav MehtaShareholding of Promoter and Promoter Group0%9,630
Board of Directors
NameDesignationYear
N R MunjalChairman / Executive Director / M D / Promoter2025
Himanshu JainED / Joint MD / Promoter2025
Rishav MehtaExecutive Director2025
Sahil MunjalExecutive Director2025
Neerja ChathleyIndependent Non Executive Women Director2025
Rajinder Kumar GuptaIndependent Non Exe. Director2025
SUBODH GUPTAIndependent Non Exe. Director2025
Prabhat KhuranaIndependent Non Exe. Director2025
Pradeep VermaVP / Company Secretary / Compliance Officer2025
Segments — Product
SegmentRevenueShare
Bulk Drugs & Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
In India₹150 Cr27.4%
Outside India₹399 Cr72.6%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹101006769
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-10Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025170203250
202500002727
202517020423
Insider / Designated-Person Trades

7 recent disclosure(s)

Essix Biosciences LimitedAcquisition · 51,00,000
Essix Biosciences LimitedAcquisition · 25,55,014
Gopal MunjalAcquisition · 2,93,579
Neera MehtaAcquisition · 2,32,057
V.R. MehtaAcquisition · 2,88,204
Sunita JainAcquisition · 2,71,860
Substantial Acquisitions (SAST)

1 disclosure(s)

Pref. Allotment21/07/2025 · 44,85,124
Company Information
Incorporated1995
ChairmanN R Munjal
AuditorRattan Kaur & Associates
Investor Email[email protected], [email protected]
🌐 www.indswiftlabs.com ↗

📍 SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Indo Tech Transformers Ltd.Indo Thai Securities Ltd.Indo Us Bio-Tech Ltd.Indowind Energy Ltd.Industrial & Prudential Investment Company Ltd.Indraprastha Medical Corporation Ltd.Indian Terrain Fashions Ltd.Indusind BankIndus Infra TrustIndus Towers LimitedInfinium Pharmachem Ltd.Influx Healthtech LimitedAll “I” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search